Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of Autologous Hematopoietic Stem Cell Transplantation Combined With BCMA-CAR-T in the Treatment of Ultra-high Risk Multiple Myeloma

NCT07109323 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07109323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07109323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of Autologous Hematopoietic Stem Cell Transplantation Combined With BCMA-CAR-T in the Treatment of Ultra-high Risk Multiple Myeloma
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 3, 2025
Completion date
March 2, 2030
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cytogenetics ultra high risk, early progression, non paraosseous extramedullary infiltration, plasma cell leukemia, primary refractory, r2-iss-iv /mpss-iv, ultra high risk mm (uhr-mm), 18-70 years old, suitable for asct. and meet any of the following uhr-mm definitions